XBiotech (NASDAQ: XBIT) — Perfil da empresa, notícias e dados financeiros
XBiotech discovers and commercializes novel antibodies, focusing on unmet needs in oncology, infectious diseases, and inflammatory conditions.
XBiotech
XBiotech (NASDAQ:XBIT) is a biopharmaceutical company engaged in discovering, developing, and commercializing novel antibodies for various diseases. The company's diverse pipeline focuses on addressing unmet medical needs in multiple therapeutic areas, emphasizing oncology, infectious diseases, and inflammatory conditions. XBiotech employs a proprietary technology platform to create unique therapeutic antibodies that aim to improve patient outcomes. Their mission revolves around harnessing the power of natural immunity to transform treatment paradigms and enhance the quality of life for patients globally. By concentrating on innovation and leveraging its research and development expertise, XBiotech strives to advance its projects from discovery through clinical development, aiming to bring groundbreaking treatments to the market.
Resumo
Operações
Produtos e/ou serviços de XBiotech
- MABp1, a first-in-class True Human monoclonal antibody targeting IL-1? for treating chronic inflammatory diseases and cancers.
- A COVID-19 therapy project aimed at developing a potent neutralizing antibody treatment for coronavirus infections.
- Research on cardiovascular diseases focusing on therapeutic antibodies to prevent and treat heart disease.
- Collaborations to develop antibody therapies for a range of infectious diseases, including potential treatments for HIV.
- Pipeline expansion efforts include identifying and developing new True Human antibodies for various inflammatory conditions and cancers.
equipe executiva do XBiotech
- John SimardFounder & Chairman
- Sushma ShivaswamyInterim CEO & Chief Scientific Officer
- Angela HuDirector of Finance
- Qian WuSenior Vice President of Clinical Operations & Analytical Quality
Histórico de dividendos
Dividendos por ação pagos pela XBiotech, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2021 | — | — | — | $2.5000 |
Principais indicadores financeiros
Resultados divulgados pela XBiotech, em USD.
- Cap. de mercado
- 56,4 mi
- Receita (TTM)
- 300 mil
- P/L
- —
- LPA (diluído, TTM)
- -1.5
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -55,7 mi | -45,5 mi | |
| 0 | -42,5 mi | -38,5 mi | |
| 300 mil | -37,5 mi | -24,6 mi | |
| 4 mi | -34,5 mi | -32,9 mi |